Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Dementia types sits at the center of this dementia and brain health question.
Dementia is not a single disease but a collection of distinct medical conditions, each with different underlying causes, progression patterns, and prognoses. Alzheimer’s disease accounts for 60-70% of all dementia cases and is by far the most common form, but vascular dementia, Lewy body dementia, frontotemporal dementia, and several other types represent the remaining cases. Understanding the differences between these conditions matters tremendously—a person diagnosed with vascular dementia due to a stroke may have a different life trajectory and treatment options than someone with Alzheimer’s disease, even though both may experience memory loss and cognitive decline.
Currently, approximately 7.4 million Americans aged 65 and older are living with Alzheimer’s disease, and about 1 in 9 people in that age group has Alzheimer’s dementia. Worldwide, an estimated 56.9 million people had dementia in 2021, a number projected to exceed 137 million by 2050 as populations age globally. These statistics underscore why it’s critical for patients, families, and caregivers to understand the specific type of dementia involved, since each form requires tailored approaches to care, treatment, and planning for the future.
Table of Contents
- What Are the Major Types of Dementia and How Common Are They?
- Understanding Alzheimer’s Disease and How It Damages the Brain
- Vascular Dementia and the Blood Supply Connection
- Lewy Body Dementia and Its Distinctive Symptoms
- Frontotemporal Dementia and Personality Changes
- Younger-Onset Dementia and Special Considerations
- Recent Breakthroughs and the Evolving Treatment Landscape
- Conclusion
What Are the Major Types of Dementia and How Common Are They?
alzheimer‘s disease dominates the dementia landscape, representing the vast majority of cases, but it’s important to recognize the other significant subtypes. Vascular dementia ranks second, representing approximately 5-10% of pure dementia cases, though when combined with other forms (mixed dementia), it accounts for about 31% of all dementia cases—affecting roughly 8.5 million people with pure vascular dementia and 9.1 million with mixed dementia.
Lewy body dementia, characterized by abnormal protein deposits called Lewy bodies throughout the brain, presents with unique symptoms including hallucinations and sleep disturbances that can be more distressing than memory loss alone. Frontotemporal dementia (FTD), a group of conditions affecting the front and side of the brain, has a pooled incidence of 2.28 per 100,000 person-years and affects about 9.17 per 100,000 people in the general population, with the behavioral variant being most common at 1.20 per 100,000 person-years. Other less common types include primary progressive aphasia, corticobasal syndrome, and progressive supranuclear palsy. The key distinction here is that while Alzheimer’s primarily affects memory in early stages, some other types—particularly FTD—strike earlier in life and may first present as personality changes, language problems, or behavioral issues rather than memory loss.
Understanding Alzheimer’s Disease and How It Damages the Brain
Alzheimer’s disease is a progressive neurodegenerative condition characterized by two hallmark pathological features: amyloid plaques that accumulate between nerve cells and neurofibrillary tangles that form inside neurons. These abnormal proteins gradually damage and kill brain cells, leading to progressive cognitive decline. The disease typically begins in the hippocampus, the brain region essential for forming new memories, which is why memory loss is often the first symptom people notice.
As the disease advances, it spreads to other brain regions, eventually affecting the ability to carry out basic functions like eating, walking, and recognizing loved ones. One important limitation to recognize is that amyloid plaques and tangles can begin accumulating in the brain years or even decades before symptoms appear, a stage called preclinical Alzheimer’s. This means some people with these brain changes may never develop symptoms during their lifetime, and others may have extensive pathology but maintain cognitive function thanks to cognitive reserve—the brain’s ability to compensate for damage. Current research, including studies with drugs like lecanemab (Leqembi) and donanemab (Kisunla), targets these amyloid deposits, but results show modest slowing of cognitive decline rather than reversal, highlighting how much more work remains to be done.
Vascular Dementia and the Blood Supply Connection
Vascular dementia results from reduced blood supply to the brain, often caused by stroke, narrowed arteries, or cerebrovascular disease. Unlike Alzheimer’s, which develops gradually, vascular dementia can sometimes have a more sudden onset, particularly when it follows a major stroke. A person might experience a stroke that causes noticeable cognitive changes almost immediately, rather than the gradual, subtle memory slips that characterize early Alzheimer’s disease. The extent of cognitive impairment depends on the location and size of the blood vessel damage—a person with small, repeated strokes affecting multiple brain regions may experience stepwise decline rather than smooth progression.
What makes vascular dementia particularly challenging is that it often indicates broader cardiovascular problems, meaning the person faces ongoing risks of future strokes and other vascular events. Managing blood pressure, diabetes, and cholesterol becomes not just health maintenance but core dementia management. Additionally, mixed dementia—where both Alzheimer’s pathology and vascular damage coexist—is increasingly recognized as more common than previously thought, affecting about 9.1 million people. This overlap complicates diagnosis and treatment, since doctors must address both underlying conditions to optimize outcomes.
Lewy Body Dementia and Its Distinctive Symptoms
Lewy body dementia (LBD) causes cognitive decline through the buildup of abnormal Lewy body proteins throughout the brain, and its symptom profile often looks quite different from Alzheimer’s disease. While memory loss does occur in LBD, people with this form of dementia frequently experience vivid visual hallucinations—seeing people, animals, or objects that aren’t there—often in the early stages. They may also suffer from movement symptoms similar to Parkinson’s disease, including tremor, muscle stiffness, and difficulty with balance and gait. Sleep disturbances are extremely common, with people experiencing restless nights, nightmares, or acting out their dreams due to REM sleep behavior disorder.
The lived experience of Lewy body dementia differs significantly from Alzheimer’s. A person might remain relatively clear-headed regarding memory and conversation but be terrorized by hallucinations of intruders in the home, or they might become immobilized by the combination of cognitive confusion and movement difficulties. This challenging symptom combination—where people are cognitively aware enough to be frightened by their hallucinations—makes LBD particularly distressing for both patients and families. Treatment approaches differ too, since certain common Alzheimer’s medications and typical antipsychotic drugs can worsen symptoms in people with LBD, requiring careful medication selection.
Frontotemporal Dementia and Personality Changes
Frontotemporal dementia primarily affects the frontal and temporal lobes of the brain, the regions responsible for personality, behavior, and language. This is why FTD often presents not with memory loss but with dramatic personality changes—a previously responsible person becoming impulsive and inappropriate, or a warm family member becoming cold and apathetic. The behavioral variant of FTD, the most common form, can be particularly troubling for families because changes in judgment, inhibition, and emotional expression often appear before any noticeable memory problems, sometimes leading to misdiagnosis as psychiatric illness or personality disorder.
One critical warning about FTD is that it strikes much earlier in life than typical Alzheimer’s disease, with many people diagnosed in their 50s or 60s. This earlier onset, combined with the dramatic behavioral changes, often creates unique stresses—loss of employment, disruption of family relationships, and the need for intensive care during what should be the peak earning and caregiving years. Additionally, FTD can involve language decline (primary progressive aphasia variants), where people gradually lose the ability to speak or understand language despite otherwise being relatively cognitively intact, creating profound isolation and communication challenges for patients and their loved ones.
Younger-Onset Dementia and Special Considerations
Dementia is often thought of as a condition of advanced age, yet approximately 200,000 Americans have younger-onset dementia—defined as dementia onset before age 65—representing a rate of about 110 per 100,000 people in the 30-64 age group. These individuals face unique challenges that older adults with dementia do not. They may still be working or have dependents relying on them; they may be raising children or serving as primary earners for their families; and they are often more socially active with larger social networks that become disrupted by cognitive decline.
Younger-onset dementia also presents diagnostic challenges, since doctors may not initially suspect dementia in a person in their 40s or 50s, leading to delays in diagnosis. A 52-year-old who begins struggling with organization at work or making poor financial decisions might first be evaluated for depression or ADHD before anyone considers dementia. The impact on identity and life plans is particularly profound—people in the prime of their careers and family responsibilities suddenly face a progressive condition that will ultimately rob them of their independence, employment, and relationships.
Recent Breakthroughs and the Evolving Treatment Landscape
The dementia research field is experiencing a period of unprecedented activity and investment. As of 2026, 158 medicines are being evaluated across 192 clinical trials for dementia conditions, representing a 40% increase in trial activity over the past decade. The pipeline has also shifted significantly, with amyloid-targeting drugs now representing only 20% of all trials, down from 33% a decade ago. This diversification reflects growing recognition that amyloid alone doesn’t explain dementia, and that multiple biological pathways—including tau tangles, neuroinflammation, vascular dysfunction, and protein misfolding—need to be addressed.
Recent research has also achieved notable breakthroughs in understanding mechanisms of disease. In May 2026, researchers announced that supramolecular nanoparticles could repair the brain’s vascular system and reverse Alzheimer’s-related cognitive decline in mice—a finding that hints at potential future approaches to address the vascular component of brain damage. The FDA has approved two amyloid-targeting drugs, lecanemab (Leqembi) and donanemab (Kisunla), both showing modest but meaningful slowing of cognitive decline in early-stage Alzheimer’s disease. Eight Phase 3 trials are expected to report results in 2026, including TRAILBLAZER-ALZ 3 evaluating donanemab in participants with mild cognitive impairment, offering hope that more options will become available.
Conclusion
Dementia is not one disease but a family of distinct conditions, each with different causes, progression patterns, and treatment approaches. Alzheimer’s disease accounts for the majority of cases, but vascular dementia, Lewy body dementia, frontotemporal dementia, and other types represent significant portions of the dementia population, each requiring individualized understanding and care. Understanding which type of dementia a person has been diagnosed with is essential for families and caregivers, as it helps set realistic expectations, guides treatment decisions, and allows for better preparation and planning.
The landscape of dementia research and treatment is changing rapidly, with new clinical trials, treatment options, and mechanistic insights emerging regularly. While no cure currently exists, the tools available to slow progression and manage symptoms are improving. For anyone facing a dementia diagnosis, or caring for someone who has received one, the most important step is getting an accurate diagnosis from a qualified neurologist or dementia specialist, understanding the specific type of dementia involved, and connecting with evidence-based care, support services, and current information as you navigate the journey ahead.
You Might Also Like
- Early-Onset Dementia Risk: The Everyday Habit Under New Scrutiny
- Early Alzheimer’s Detection: Why Blood Tests Could Change Dementia Screening
- Alzheimer’s vs. Lewy Body Dementia: Key Differences Families Should Know
For more, see Alzheimer’s Association — clinical trials.
